Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Intra-Cellular Therapies Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 8, 2017 7:30 AM ESTNEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the third quarter ended September 30, 2017, and provided a corporate update.
Third Quarter 2017 Financial Results
Intra-Cellular Therapies (the Company or ITCI) reported a net loss of $22.9 million, or $0.53 per share (basic and diluted), for the third quarter of 2017 compared to a net loss of $30.3 million, or $0.70 per share (basic and diluted), for the third quarter of 2016.
Research... More
